Drugs / RP902
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07579884 | May 2026 → May 2029 expected | cognitive disorder | Risen (Suzhou) Pharma Tech Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RP902 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07579884 ↗ |